Alkermes ALKS

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.12 (-0.37%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Alkermes (ALKS) Business Model and Operations Summary
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Key Insights

Alkermes (ALKS) Core Market Data and Business Metrics
  • Latest Closing Price

    $32.65
  • Market Cap

    $5.31 Billion
  • Price-Earnings Ratio

    -15.26
  • Total Outstanding Shares

    162.61 Million Shares
  • Total Employees

    1,800
  • Dividend

    No dividend
  • IPO Date

    July 16, 1991
  • SIC Description

    Pharmaceutical Preparations
  • Primary Exchange

    NASDAQ
  • Headquarters

    Connaught House, Dublin 4, L2, 00000

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Short Interest

Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
Avg Daily VolumeDays to CoverSettlement DateShort Interest
1,790,398 Shares7.233/14/202512,951,480 Shares
1,535,719 Shares9.122/28/202514,008,923 Shares
2,326,666 Shares4.972/14/202511,574,847 Shares
1,506,986 Shares7.181/31/202510,824,850 Shares
1,285,335 Shares8.851/15/202511,369,150 Shares
1,746,596 Shares6.1512/31/202410,736,401 Shares

Cash Flow Statement

October 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Financing Activities$-59,000
Net Cash Flow From Operating Activities$-47.77 Million
Net Cash Flow From Investing Activities$-43,000
Net Cash Flow$-47.87 Million
Net Cash Flow From Financing Activities, Continuing$-59,000
Net Cash Flow, Continuing$-47.87 Million

Income Statement

October 1, 2024 to December 31, 2024
MetricValue
Nonoperating Income/Loss$5.40 Million
Research and Development$50.17 Million
Interest Income/Expense Operating, Net$5.39 Million
Basic Earnings Per Share$-1.07
Operating Expenses$67.02 Million
Diluted Earnings Per Share$-1.07

Comprehensive Income

October 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss$-57.96 Million
Comprehensive Income/Loss Attributable To Parent$-57.96 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$0

Balance Sheet

October 1, 2024 to December 31, 2024
MetricValue
Equity$486.93 Million
Other Non-current Assets$58.62 Million
Accounts Payable$7.77 Million
Liabilities And Equity$547.11 Million
Wages$14.47 Million
Other Current Liabilities$26.26 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ALKS from trusted financial sources

    Related Companies

    Publicly traded companies similar to Alkermes (ALKS)